Since 2002, the Joseph C. Monastra (JCM) Foundation for Pancreatic Cancer Research has been supporting a talented group of scientists at Johns Hopkins Medical Institutions dedicated to making significant strides towards understanding how Pancreatic Cancer develops and spreads.
Today, thanks to advances in cancer genetics made by the team at Johns Hopkins we now understand that pancreatic cancer is fundamentally a genetic disease- a disease caused by inherited and acquired DNA mutations. Because of this fundamental advance made by Hopkins researchers we can now attack pancreatic cancer on multiple fronts. The research program at Johns Hopkins is broad and deep with over 20 full-time faculty members, and it includes:
- basic science studies of how the pancreas forms embryologically,
- cutting-edge genetic analyses of surgically resected cancers,
- studies of the genetics of familial pancreatic cancer,
- research into the precursor lesions that give rise to invasive pancreatic cancer,
- the development of new screening tests for early pancreatic cancer (just as there is a PSA test for prostate cancer, so too do we need a test for early curable pancreatic cancer),
- the development and testing of new therapies including a novel vaccine-based therapy to treat pancreatic cancer, and
- studies of advanced/metastatic pancreatic cancer.
Simply put, today we can attack pancreatic cancer in the lab in ways that we could not have imagined ten years ago.
To learn more about the Pancreatic Cancer research supported in part by the JCM Foundation please visit our Research page.
The Pancreatic Cancer Sequencing Team in the Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins University received the Seventh Annual American Association for Cancer Research (AACR) Team Science Award. The AACR Team Science Award recognizes an outstanding interdisciplinary research team for its innovative and meritorious scientific work that has advanced or will likely advance cancer research, detection, diagnosis, prevention or treatment. This multi-institutional team was selected based on its tremendous impact on understanding of the fundamental genetic changes that characterize pancreatic cancer. Working together for 10 years, the interdisciplinary team, led by Ralph H. Hruban, M.D., of Johns Hopkins, comprises 20 faculty members from three different institutions: Johns Hopkins University in Baltimore, Md.; Emory University in Atlanta, Ga.; and Memorial Sloan-Kettering Cancer Center in New York, N.Y. Emory’s research was led by Volkan Adsay, MD, professor of pathology and laboratory medicine in Emory University School of Medicine, and a member of the Winship Cancer Institute at Emory.
(Pictured Right from top to bottom: Team Science Award Honorees – Johns Hopkins, Emory University & Sloan Ketting; Dr. Christine Iacobuzio-Donahue; Dr. Ralph Hruban receiving team science award from AACR; Dr. Ralph Hruban)